| Modeling pancreatic cancer in vivo: from xenograft and carcinogen-induced systems to genetically engineered mice. | |
| | |
MedLine Citation:
|
PMID: 20335777 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In the last 10 years, there has been a relative explosion of new rodent systems that recapitulate both genetic and cellular lesions that lead to the development of pancreatic cancer. These models now need to be considered when selecting an appropriate in vivo system to study disease etiology, cell signaling, and drug development. The majority of these evaluations have used transplantation of cancer cells and the use of carcinogens, which still maintain their value when investigating human cancer and epigenetic contributors. Xenograft models utilize cultured or primary pancreatic cancer cells that are placed under the skin or implanted within the pancreas of immunocompromised mice. Carcinogen-induced systems rely on administration of certain chemicals to generate cellular changes that rapidly lead to pancreatic cancer. Genetically modified mice are more advanced in their design in that relevant genetic mutations can be inserted into mouse genomic DNA in both a conditional and inducible manner. Generation of mice that develop spontaneous pancreatic cancer from a targeted genetic mutation is a valuable research tool, considering the broad spectrum of genes and cell targets that can be used, producing a variety of neoplastic lesions and cancer that can reflect many aspects of human pancreatic ductal adenocarcinoma. |
| | |
Authors:
|
Yongzeng Ding; John D Cravero; Kevin Adrian; Paul Grippo |
Related Documents
:
|
12789847 - Management of pancreatic cancer. 20119937 - Psychological distress in patients with pancreatic cancer--an understudied group. 7591227 - Prior immunity-related medical conditions and pancreatic-cancer risk in shanghai. 21566457 - Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. 8706247 - Transferrin c3 offers protection against smoking-associated lung cancer? 2144997 - Does nutrition management benefit the head and neck cancer patient? |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Pancreas Volume: 39 ISSN: 1536-4828 ISO Abbreviation: Pancreas Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-03-25 Completed Date: 2010-07-08 Revised Date: 2011-06-01 |
Medline Journal Info:
|
Nlm Unique ID: 8608542 Medline TA: Pancreas Country: United States |
Other Details:
|
Languages: eng Pagination: 283-92 Citation Subset: IM |
Affiliation:
|
Department of Surgery, Northwestern University, Chicago, IL 60611, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Carcinogens / pharmacology Cell Transformation, Neoplastic / genetics, pathology Disease Models, Animal* Homeodomain Proteins / genetics Humans Keratins / genetics Mice* Mice, Knockout Mice, Transgenic Pancreatic Elastase / genetics Pancreatic Neoplasms* / chemically induced, genetics, pathology Trans-Activators / genetics Transcription Factors / genetics Xenograft Model Antitumor Assays |
| Chemical | |
Reg. No./Substance:
|
0/Carcinogens; 0/Homeodomain Proteins; 0/Trans-Activators; 0/Transcription Factors; 0/pancreatic and duodenal homeobox 1 protein; 0/transcription factor PTF1; 68238-35-7/Keratins; EC 3.4.21.36/Pancreatic Elastase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Musculoskeletal manifestations of ehlers-danlos syndrome.
Next Document: Clinicopathological significance of cell cycle regulatory factors and differentiation-related factor...